Healthcare · Profile from Healthcare Research Companion
AbbVie Inc.
The research-based pharmaceutical company that Abbott Laboratories spun off in 2013 to hold Humira, then the world's best-selling drug. AbbVie's story is the clearest modern case of a single-product company managing a patent cliff: it extended Humira's US exclusivity to 2023 with a dense patent estate and settlements, used the cash to buy Pharmacyclics (2015) and Allergan (2020), and built two successor immunology drugs, Skyrizi and Rinvoq, that by 2025 sold more than Humira ever did. It also carries some of the industry's most expensive failed bets, from the abandoned Shire inversion to Stemcentrx and Cerevel's schizophrenia drug.
At a glance
- Founded
- 1 January 2013, as a spin-off of Abbott's research-based pharmaceuticals business (Abbott's drug roots go back to 1888)
- Founders
- Created by Abbott under CEO Miles White; Richard (Rick) Gonzalez was AbbVie's first chairman and CEO
- Headquarters
- North Chicago, Illinois (Lake County), next to Abbott's historic campus
- Ownership / structure
- Public company, NYSE: ABBV; Abbott shareholders received one AbbVie share per Abbott share; inherited Abbott's long dividend record
- Leadership (2026)
- Robert (Rob) Michael, CEO since 1 July 2024 and also chairman since 1 July 2025, when founding CEO and chairman Rick Gonzalez retired from the board (AbbVie, 14 Feb 2025); Scott Reents, CFO (from 2024, reported)
- Segment and buyer
- Branded pharmaceuticals and aesthetics: immunology, oncology, neuroscience, eye care, aesthetics (Botox Cosmetic, Juvéderm). Payers are commercial plans and their PBMs, Medicare Part D and Part B, Medicaid; aesthetics is paid out of pocket by consumers through physicians and medical spas
- Scale
- 2025 net revenue ~$61.2bn (+8.6%, reported); immunology ~$30.4bn; Skyrizi ~$17.6bn, Rinvoq ~$8.3bn, Humira ~$4.5bn (2025, reported); ~55,000–57,000 employees (company letters 2024–25, reported)
- Capital / market cap
- Self-funding; heavy debt raised for Allergan (~$40bn+ of acquisition debt, since largely paid down, reported); market cap roughly ~$400bn in 2026 (market data, approximate)
- Signature moves (incl. failures)
- Humira approval (2002, under Abbott); spin-off from Abbott (2013); Shire inversion agreed and abandoned (2014); Pharmacyclics/Imbruvica (2015); Stemcentrx (2016, written off); Humira patent estate and biosimilar settlements (2016–2023); Skyrizi and Rinvoq launches (2019); Allergan (2020); ImmunoGen and Cerevel (2023–24), with the emraclidine failure (2024)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2002
Humira Approval and Knoll Deal
Acquisition (Knoll, 2001) and launch (Humira, 2002–03)
2013
Spin Off from Abbott
Spin-off
2014
Shire Inversion Abandoned
Acquisition (failed) / tax inversion
2016
Stemcentrx Rova T Write Off
Acquisition / write-down
2017
Humira Patent Thicket and Biosimilar Delay
IP strategy / litigation settlement
2019
Skyrizi and Rinvoq Launches
Launch
2020
Allergan Acquisition
Acquisition
2024
Cerevel and Emraclidine Failure
Acquisition / write-down